Import Your Data

FAQ

More QuickView FAQs

QuickView

0
Meta-
Analysis

Bookmark Forward

QuickView for Degarelix (compound)

Summary
General Info

DrugBank

Identification

Name:	degarelix
Name (isomeric):	DB06699
Drug Type:	small molecule
Brand:	Firmagon
Category:	Antineoplastic Agents, Hormonal, Antineoplastic Agents, Antineoplastics
CAS number:	214766-78-6

Pharmacology

Indication:	Degaralix is used for the management of advanced prostate cancer. Its action ultimately results in a reduction in circulating androgens, which provides a therapeutic benefit by reducing the growth stimulus used by hormone-sensitive malignant prostate tissue.
Pharmacology:	Degarelix is a synthetic derivative of GnRH decapeptide which normally stimulates the GnRH receptor. Gonadotropin and androgen production result from the binding of endogenous GnRH to the GnRH receptor. The ability of Degarelix to antagonize GnRH at its receptor and suppress the release of these hormones is what gives it potency in slowing advanced... show more » Degarelix is a synthetic derivative of GnRH decapeptide which normally stimulates the GnRH receptor. Gonadotropin and androgen production result from the binding of endogenous GnRH to the GnRH receptor. The ability of Degarelix to antagonize GnRH at its receptor and suppress the release of these hormones is what gives it potency in slowing advanced prostate cancer. Degarelix antagonizes the GnRH receptor which in turn blocks the release of LH and FSH from the pituitary. The reduction in LH leads to a decrease in testosterone release from the testes and subsequently reduces the size and growth of the prostate cancer. show less «
Mechanism of Action:	GnRH antagonists compete with natural GnRH for binding to GnRH receptors in the pituitary gland. This reversible blinding blocks the release of LH and FSH from the pituitary. The reduction in LH subsequently leads to a rapid and sustained suppression of testosterone release from the testes and subsequently reduces the size and growth of the prostat... show more » GnRH antagonists compete with natural GnRH for binding to GnRH receptors in the pituitary gland. This reversible blinding blocks the release of LH and FSH from the pituitary. The reduction in LH subsequently leads to a rapid and sustained suppression of testosterone release from the testes and subsequently reduces the size and growth of the prostate cancer. show less «
Absorption:	Degarelix forms a depot at the site of injection after subcutaneous administration from which the drug slowly released into circulation. Peak plasma concentrations of degarelix generally occur within 2 days following subcutaneous administration of a single 240-mg dose at a concentration of 40 mg/mL.
Protein binding:	90% of the drug is bound to plasma proteins.
Biotransformation:	Degarelix is subject to peptide hydrolysis during its passage through the hepatobiliary system and is mainly excreted as peptide fragments in feces. Approximately 20-30% of a given dose of degarelix is renally eliminated, suggesting that approximately 70-80% is excreted via the hepatobiliary system.
Half Life:	23-61 days
Affected organisms:	Humans and other mammals

Interactions

Drug interaction:

Additive QTc-prolongation may occur. Concomitant therapy should be avoided.

Targets

Gonadotropin-releasing hormone receptor